The MarketWatch News Department was not involved in the creation of this content. bioAffinity Technologies' noninvasive diagnostic shifted the course of care from watchful waiting for up to 5 years to ...
In a 2024 Journal of Thoracic Oncology review, Haiquan Chen, MD, PhD, of Fudan University Shanghai Cancer Center in China, and colleagues backed the use of selective lymph node dissection (LND) to ...
Lung cancer, the most commonly diagnosed cancer in China, has only a 19.7% five-year survival rate in the country. The disease in non-smokers is prevalent and younger patients account for an ...
The U.K. company presented findings that its 360 e-Lung technology could potentially speed up the diagnosis of progressive pulmonary fibrosis by nearly two years in more than half of the patients ...
bioAffinity Technologies’ noninvasive diagnostic shifted the course of care from watchful waiting for up to 5 years to confirmed malignancy and immediate treatment Ground-glass nodules appear in ...
bioAffinity Technologies’ noninvasive diagnostic shifted the course of care from watchful waiting for up to 5 years to confirmed malignancy and immediate treatment SAN ANTONIO--(BUSINESS WIRE)-- ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback